Research Paper Volume 15, Issue 14 pp 7098—7123
Comparative analyses of the prognosis, tumor immune microenvironment, and drug treatment response between left-sided and right-sided colon cancer by integrating scRNA-seq and bulk RNA-seq data
Figure 7. Prediction and comparison of the drug response in LCC and RCC patients based on TCGA-COAD cohort. (A) The expression of immune checkpoint targets was significantly higher in TMB-high patients than in TMB-low patients. (B) The expression of immune checkpoint targets was significantly higher in RCC patients than in LCC patients. (C) The expression of immune checkpoint targets was significantly higher in high-risk than low-risk LCC patients. (D) Comparison of immune checkpoint target expression between high-risk and low-risk RCC patients. (E) Sensitivity to the eight drugs did not differ significantly between LCC and RCC patients. (F) Drug response sensitivity did not differ significantly between high-risk and low-risk LCC patients. (G–N) Correlations between the average IC50 values of the eight drugs and RCC patient risk scores.